
TY  - JOUR
TI  - HEALTH SERVICES, ECONOMICS AND OUTCOME MEASURES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_12.x
DO  - doi:10.1111/j.1479-8077.2006.00199_12.x
SP  - A68
EP  - A78
PY  - 2006
ER  - 

TY  - JOUR
TI  - HUMORAL ASPECTS OF AUTOIMMUNE DISEASES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_13.x
DO  - doi:10.1111/j.1479-8077.2006.00199_13.x
SP  - A79
EP  - A80
PY  - 2006
ER  - 

TY  - JOUR
TI  - OTHERS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_21.x
DO  - doi:10.1111/j.1479-8077.2006.00199_21.x
SP  - A142
EP  - A159
PY  - 2006
ER  - 

TY  - JOUR
TI  - SYSTEMIC LUPUS ERYTHEMATOSUS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_30.x
DO  - doi:10.1111/j.1479-8077.2006.00199_30.x
SP  - A253
EP  - A274
PY  - 2006
ER  - 

TY  - JOUR
TI  - VASCULITIS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_31.x
DO  - doi:10.1111/j.1479-8077.2006.00199_31.x
SP  - A274
EP  - A278
PY  - 2006
ER  - 

TY  - JOUR
AU  - Suyavaran, Arumugam
AU  - Thirunavukkarasu, Chinnasamy
C8  - HEPRES-15-1046.R1
TI  - Preconditioning methods in the management of hepatic ischemia reperfusion- induced injury: Update on molecular and future perspectives
JO  - Hepatology Research
JA  - Hepatol Res
VL  - 47
IS  - 1
SN  - 1386-6346
UR  - https://doi.org/10.1111/hepr.12706
DO  - doi:10.1111/hepr.12706
SP  - 31
EP  - 48
KW  - apoptosis
KW  - hepatic ischemia/reperfusion
KW  - inflammation
KW  - necrosis
KW  - preconditioning
PY  - 2017
AB  - Hepatic IR (ischemia reperfusion) injury is a commonly encountered obstacle in the post-operative management of hepatic surgery. Hepatic IR occurs during ?Pringle maneuver? for reduction of blood loss or during a brief period of cold storage followed by reperfusion of liver grafts. The stress induced during hepatic IR, triggers a spectrum of cellular responses leading to the varying degrees of hepatic complications which in turn affect the post operative care. Different preconditioning methods either activate or subdue different sets of molecular signals, resulting in varied levels of protection against hepatic IR injury. Yet, there is a serious lacuna in the knowledge regarding the choice of preconditioning methods and the resulting molecular changes in order to assess the efficiency and choice of these methods correctly. This review provides an update on the various preconditioning approaches such as surgical/ischemic, antioxidant, pharmaceutical and genetic preconditioning strategies published during last six years (2009?2015). Further, we discuss the attenuation or inhibition of specific inflammatory, apoptotic and necrotic markers in the various experimental models of liver IR subjected to different preconditioning strategies. While enlisting the controversies in the ischemic preconditioning strategy, we bring out the uncertainties in the existing molecular targets and their reliability in the attenuation of hepatic IR injury. Future research studies would include the novel preconditioning strategies employ i) the targeted gene silencing of key molecular targets inducing IR, ii) hyper expression of beneficial molecular signals against IR via gene transfer techniques. The above studies would see the combination of these latest techniques with the established preconditioning strategies for better post-operative hepatic management.
ER  - 

TY  - JOUR
TI  - Abstracts presented at the 30th Annual VCS Conference, San Diego, CA, USA, 29 October–1 November 2010
JO  - Veterinary and Comparative Oncology
VL  - 9
IS  - 1
SN  - 1476-5810
UR  - https://doi.org/10.1111/j.1476-5829.2010.00252.x
DO  - doi:10.1111/j.1476-5829.2010.00252.x
SP  - e1
EP  - e49
PY  - 2011
ER  - 

AU  - Marshall, John C.
AU  - Malam, Zeenat
AU  - Jia, Songhui
C7  - pp. 53-72
TI  - Modulating Neutrophil Apoptosis
SN  - 9780470027981
UR  - https://doi.org/10.1002/9780470059593.ch5
DO  - doi:10.1002/9780470059593.ch5
SP  - 53-72
KW  - modulating neutrophil-apoptosis
KW  - Polymorphonuclear neutrophils (PMNs)
KW  - bystander injury to host tissues in neutrophil activation
KW  - cellular mechanisms inhibiting apoptosis
KW  - pre-colony B cell enhancing factor (PBEF)
PY  - 2011
AB  - Summary Polymorphonuclear neutrophils are short-lived phagocytic cells that serve as cardinal early cellular effectors of innate immunity. Both oxidative and non-oxidative mechanisms contribute to microbial killing by the neutrophil. Neutrophil defence mechanisms are potent but non-specific, with the result that inadvertent injury to host tissues commonly accompanies the activation of a neutrophil-mediated response; this bystander injury has been implicated in the tissue injury of sepsis. The capacity for neutrophils to cause injury to host tissues is attenuated by the relatively short in vivo lifespan of the neutrophil, a consequence of a constitutively expressed program of apoptosis. That program can be inhibited, and neutrophil survival prolonged, through the interaction of the neutrophil with a variety of mediators of both microbial and host origin. These, in turn, inhibit apoptosis by increasing the expression of anti-apoptotic genes within the neutrophil: interleukin (IL)1? and a novel cytokine-like molecule pre-B cell colonyenhancing factor (PBEF) are central to this inhibitory influence. Conversely, the phagocytosis of a micro-organism activates the apoptotic program, and so contributes to the resolution of acute inflammation. A complex series of interactions between the neutrophil and microorganisms or their products regulates the duration and intensity of an inflammatory response, and so provides an attractive target for therapeutic manipulation.
ER  - 

TY  - JOUR
TI  - 2017 Annual Meeting of the American Society for Bone and Mineral Research, Colorado Convention Center, Denver, CO, USA — September 8–11, 2017
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 32
IS  - S1
SN  - 9780470027981
UR  - https://doi.org/10.1002/jbmr.3363
DO  - doi:10.1002/jbmr.3363
SP  - S1
EP  - S432
PY  - 2017
ER  - 

TY  - JOUR
TI  - CELL RECEPTOR-LIGAND INTERACTION, SIGNALING AND ACTIVATION
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_6.x
DO  - doi:10.1111/j.1479-8077.2006.00199_6.x
SP  - A39
EP  - A39
PY  - 2006
ER  - 

TY  - JOUR
TI  - CYTOKINES AND INFLAMMATORY MEDIATORS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_7.x
DO  - doi:10.1111/j.1479-8077.2006.00199_7.x
SP  - A39
EP  - A45
PY  - 2006
ER  - 

TY  - JOUR
TI  - GENOMICS, GENETIC BASIS OF DISEASE AND HLA/T CELL RECOGNITION
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_11.x
DO  - doi:10.1111/j.1479-8077.2006.00199_11.x
SP  - A66
EP  - A68
PY  - 2006
ER  - 

TY  - JOUR
TI  - INFECTION-RELATED RHEUMATIC DISEASES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_14.x
DO  - doi:10.1111/j.1479-8077.2006.00199_14.x
SP  - A80
EP  - A83
PY  - 2006
ER  - 

TY  - JOUR
TI  - MISCELLANEOUS RHEUMATIC DISEASES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_16.x
DO  - doi:10.1111/j.1479-8077.2006.00199_16.x
SP  - A90
EP  - A99
PY  - 2006
ER  - 

TY  - JOUR
TI  - OSTEOPOROSIS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_20.x
DO  - doi:10.1111/j.1479-8077.2006.00199_20.x
SP  - A125
EP  - A142
PY  - 2006
ER  - 

TY  - JOUR
TI  - SPONDYLOARTHROPATHIES INCLUDING PSORIATIC ARTHRITIS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_28.x
DO  - doi:10.1111/j.1479-8077.2006.00199_28.x
SP  - A234
EP  - A247
PY  - 2006
ER  - 

TY  - JOUR
TI  - BACK PAIN
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_3.x
DO  - doi:10.1111/j.1479-8077.2006.00199_3.x
SP  - A26
EP  - A31
PY  - 2006
ER  - 

TY  - JOUR
TI  - BONE DISEASES OTHER THAN OSTEOPOROSIS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_4.x
DO  - doi:10.1111/j.1479-8077.2006.00199_4.x
SP  - A31
EP  - A33
PY  - 2006
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 56
IS  - S1
SN  - 9780470027981
UR  - https://doi.org/10.1002/hep.26040
DO  - doi:10.1002/hep.26040
SP  - 191A
EP  - 1144A
PY  - 2012
ER  - 

TY  - JOUR
TI  - MYOPATHIES AND SOFT TISSUE RHEUMATISM INCLUDING FIBROMYALGIA
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_17.x
DO  - doi:10.1111/j.1479-8077.2006.00199_17.x
SP  - A99
EP  - A101
PY  - 2006
ER  - 
